To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
Gastric cancer confirmed by histopathological or cytological diagnosis;
unresectable locally advanced or recurrent/metastatic gastric cancer;
age 18-75 years, regardless of gender;
ECOG score 0-2;
Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment;
Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction;
Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment);
Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded);